Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMKDP57)

Drug Name

Safotibant Drug Info

Synonyms

UNII-02HU8HWP7U; 02HU8HWP7U; 633698-99-4; CHEMBL1254771; LF22-0542; LF-22-0542; Safotibant [INN]; Lf 22-0542; SCHEMBL1723565; DTXSID20212769; BDBM50326708; N-((4-(4,5-Dihydro-1H-imidazol-2-yl)phenyl)methyl)-2-(2-(((4-methoxy-2,6-dimethylphenyl)sulfonyl)methylamino)ethoxy)-N-methylacetamide; N-((4-(4,5-Dihydro-1H-imidazol-2-yl)phenyl]methyl)-2-(2-((4-methoxy-2,6-dimethylbenzenesulfonyl)(methyl)amino]ethoxy)-N-methylacetamide; Acetamide, N-((4-(4,5-dihydro-1H-imidazol-2-yl)phenyl)methyl)-2-(2-(((4-meth

Indication

Disease Entry	ICD 11	Status	REF
Diabetic macular edema	9B71.02	Phase 2	[1]

Cross-matching ID

PubChem CID: 11953367
CAS Number: CAS 633698-99-4
TTD Drug ID: DMKDP57

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting B1 bradykinin receptor (BDKRB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
SSR-240612	DMFNZPY	Rheumatoid arthritis	FA20	Phase 2	[3]
BI 113823	DMUJ1EL	Osteoarthritis	FA00-FA05	Phase 1	[4]
H-DArg-Arg-Pro-Hyp-Gly-Igl-Ser-D-BT-OH(JMV1638)	DM6839G	Discovery agent	N.A.	Investigative	[5]
H-Lys-Arg-Pro-Hyp-Gly-Thi-Ser-D-BT-OH(JMV1669)	DMTGU0L	Discovery agent	N.A.	Investigative	[5]
Des-Arg(9)-[Leu(8)]-BK	DMVX9I0	Depression	6A70-6A7Z	Investigative	[6]
H-Lys-Arg-Pro-Hyp-Gly-Igl-Ser-D-BT-OH(JMV1645)	DMDXIS7	Discovery agent	N.A.	Investigative	[5]
JMV1431	DMAR3M2	Discovery agent	N.A.	Investigative	[5]
Ac-Lys-[Leu(8)]-des-Arg(9)-BK	DMIAYTP	Discovery agent	N.A.	Investigative	[7]
NVP-SAA164	DMN90R6	Pain	MG30-MG3Z	Investigative	[8]
Des-Arg10-Kallidin	DMZ5Y94	Discovery agent	N.A.	Investigative	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
B1 bradykinin receptor (BDKRB1)	TTG5QIA	BKRB1_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT01319487) Safety and Efficacy Study of Topical Administration of FOV2304 (High Dose or Low Dose) for the Treatment of Center-involving Clinically Significant Macular Edema Associated With Diabetic Retinopathy. U.S. National Institutes of Health.
2	The role of kinin receptors in cancer and therapeutic opportunities. Cancer Letters Volume 345, Issue 1, 1 April 2014, Pages 27-38.
3	The kinin B1 receptor antagonist SSR240612 reverses tactile and cold allodynia in an experimental rat model of insulin resistance. Br J Pharmacol. 2007 September; 152(2): 280-287.
4	The bradykinin B1 receptor antagonist BI113823 reverses inflammatory hyperalgesia by desensitization of peripheral and spinal neurons. Eur J Pain. 2015 Jan;19(1):132-42.
5	Synthesis and biological evaluation of bradykinin B(1)/B(2) and selective B(1) receptor antagonists. J Med Chem. 2000 Jun 15;43(12):2382-6.
6	Evidence for the participation of kinins in Freund's adjuvant-induced inflammatory and nociceptive responses in kinin B1 and B2 receptor knockout mice. Neuropharmacology. 2001 Dec;41(8):1006-12.
7	Non-competitive pharmacological antagonism at the rabbit B(1) receptor. Br J Pharmacol. 2000 Nov;131(5):885-92.
8	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 659).
9	Development of an efficient and selective radioligand for bradykinin B1 receptor occupancy studies. Bioorg Med Chem Lett. 2004 Dec 20;14(24):6045-8.